Revolution Medicines has delivered very strong long term shareholder returns over the past five years, yet the broader valuation checks now suggest the stock is priced on the rich side rather than as a clear bargain.

• Revolution Medicines has returned about 7x over the past 5 years, which puts extra pressure on today’s buyers to justify the current share price.
• Recent interest around its RAS(ON) inhibitor partnerships and demand for daraxonrasib can support high growth expectations, but the development and commercial risks in oncology may still weigh heavily on how much investors are willing to pay.
• On Simply Wall St’s broader framework, the stock only passes 2 of 6 valuation checks, which leans more toward expensive than clearly underpriced.

The issue now is whether Revolution Medicines’ current price still offers enough potential reward to compensate for that fuller valuation and the risks attached to its pipeline.

Has Revolution Medicines Run Too Far on Book Value?

P/B is a useful lens for Revolution Medicines because the company is still loss making and investors are leaning more on its asset base and pipeline value than on earnings. On this measure, Revolution Medicines trades at a P/B of about 16.9x. That is well above the US Biotechs industry average of about 2.4x and also ahead of the peer group average around 9.6x.

The Simply Wall St framework flags this gap as extreme. The model is heavily penalising the current losses and risk profile, so the large premium reads more like a warning sign than a precise estimate of fair value. Despite recent excitement around daraxonrasib demand and the BeOne Medicines partnership, the current P/B multiple still implies investors are paying a high price relative to the book value that supports the stock.

On the P/B multiple alone, Revolution Medicines currently screens as overvalued compared with both its industry and peers.

The Revolution Medicines Narrative: What Would Justify Today's Price?

Simply Wall St Narratives take the valuation puzzle around Revolution Medicines and turn it into a set of clear, testable stories about what its future could look like. Each narrative spells out the growth, margin and earnings assumptions that would need to hold for Revolution Medicines' stock to be worth materially more or less than today’s price, and lays out those assumptions so you can compare them with actual results over time. Narratives for Revolution Medicines sit on Simply Wall St’s Community page and are designed to help you judge whether the expectations behind the current P/B multiple feel reasonable for your own approach.

Community views on Revolution Medicines sit far apart, with one side leaning into the RAS oncology upside and the other highlighting how much is already priced in.

Bull case: 25% undervalued

"A large late stage clinical footprint, including 8 ongoing or planned Phase III registrational trials and more than 2,500 patients treated, positions the company to potentially convert its pipeline into commercial products across several tumor types, which could be important for future revenue and earnings scale…"

Bear case: roughly fairly valued

"Revolution Medicines currently reports no revenue and a net loss of $364.9 million in the fourth quarter of 2025, and guidance for 2026 GAAP operating expenses of $1.6b to $1.7b highlights a prolonged period of heavy cash use that could weigh on future earnings and delay any path to positive net margins…"

Do you think there's more to the story for Revolution Medicines? Head over to our Community to see what others are saying!

The Bottom Line

Revolution Medicines now screens as overvalued on market multiples, with a particularly wide gap between its P/B ratio and both the industry and peer averages. The low overall value score reinforces that the broader set of checks is not giving strong support to the current valuation. For potential investors, the key question is whether the oncology pipeline, including RAS(ON) programs like daraxonrasib, can eventually justify that premium or whether today’s pricing already assumes too much success.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.